Australia: Codeine—prescription only

Last Updated: 15 May 2018
Article by Jehan Mata

As a result of new regulatory changes, Australians can no longer purchase over-the-counter (OTC) medications containing codeine. As of 1 February 2018, all codeine-based products previously available OTC are now only obtainable by prescription. The most common analgesics containing codeine are Nurofen Plus and Panadeine.

Why the change?
These changes to regulations have arisen from an increase in fatal codeine-related overdoses in Australia. OTC codeine products were previously widely and readily available. There have been several years of government scrutiny regarding the use and abuse of OTC medications containing codeine. It is estimated that approximately 600,000 Australians misuse OTC codeine products and each year nearly 100 people die from this cause. In 2015, the Advisory Committee on Medicine Scheduling sought public submissions and consultation on the use and misuse of OTC codeine products.

In submissions to the Therapeutic Goods Association, doctors reported their patients taking between 60 and 100 pills (OTC codeine containing paracetamol or ibuprofen) daily. These patients typically began taking low doses to combat moderate to severe pain. They often had a history of trauma and depression, which, coupled with the addictive properties of codeine, lead them to abuse the medication. Submissions to the Therapeutic Goods Association also suggested that many consumers are unaware of the significant risks associated with taking OTC codeine products in large doses or for an extended period of time, which underpinned the move towards making them prescription only medication.

Before the recent changes, consumers were limited to the purchase of five days' supply of codeine-based medications in one transaction. Addicts and professionals in the medical and addiction fields reported that "pharmacy-shopping" was widespread. Medical professionals supporting the changes have also emphasised that OTC codeine-containing analgesics often provide little additional benefits compared to similar analgesics without codeine. These products contain less than 30 mg, which some say is not enough codeine to have a significant effect on pain. This may also lead patients to increase their dose to obtain relief.

What are the legal changes?
The delegate to the Secretary of the Department of Health has amended the Standard for the Uniform Scheduling of Medicines and Poisons (also referred to as SUSMP or Poisons Standard) under the Therapeutic Goods Regulations 1990. From 1 February 2018, codeine products were removed from Schedules 2 and 3 (which cover OTC medication able to be purchased at pharmacies), leaving codeine products in Schedule 4 (by prescription only) and Schedule 8 (controlled substances).

What does this mean for doctors?
These changes effectively place an increased onus on doctors to detect and prevent codeine addiction. Codeine overdose fatalities are increasingly scrutinised by the Coroner's Court and the Australian Health Practitioner Regulation Agency. In light of these changes, doctors must ensure:

  • their practices are reviewed and compliant
  • detailed and accurate records are maintained
  • prescriptions are provided in line with clinical indications, and
  • patients at risk, or already in the throes of addiction, are alerted to the risks.

Practitioners must undertake a thorough review of patient needs and demonstrate vigilance when prescribing codeine medications. For the practitioner's own protection, this should be reflected in the clinical records.

Several professionals in the field have suggested these changes will push doctors to develop their practise of pain management and treatment. Some are hopeful doctors will look to alternate treatment and focus on the psychological aspects of pain management. It has been suggested this change of focus is already growing in the medical community.

What does this mean for pharmacists?
Some pharmacists have been critical of the scheduling changes—in the past, it was largely up to them to monitor the supply of OTC codeine products and if they believed a customer was abusing codeine, had the discretion to refuse supply and direct them to a general practitioner (GP).

The Pharmacy Guild of Australia developed MedASSIST—a real-time monitoring system that allowed pharmacists to find out if a customer had recently purchased OTC codeine products. While the system was voluntary, pharmacies that implemented it were reporting positive results. MedASSIST has now been discontinued by the Pharmacy Guild as it felt it had been rendered obsolete by the scheduling changes.

What's next?
There is consumer backlash, with chronic pain sufferers expressing concerns about not being able to treat pain at the onset. Instead, they may be required to wait hours or days to schedule an appointment with their GP. The scheduling is also likely to result in increased Medicare and Pharmaceutical Benefits Scheme costs.

The Australian Medical Association has warned that these changes alone are unlikely to address the issue of abuse and dependency. It has called for improved education for consumers and practitioners, as well as real-time monitoring of prescriptions and dispenses. Real-time monitoring can help reduce doctor and/or pharmacy "shopping" and help people struggling with addiction.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Jehan Mata
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions